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Abstract
Background: Pneumocystis jiroveci pneumonia (PJP) in non-HIV patients is still a challenge for intensivists. The aim
of our study was to evaluate mortality predictors of PJP patients requiring Intensive care unit (ICU) admission.
Methods: Retrospectively review medical records of patients with diagnosis of PJP admitted to four ICUs of two
academic medical centers from October 2012 to October 2015.
Results: Eighty-two patients were enrolled in the study. Overall hospital mortality was 75.6 %. Compared with
survivors, the non-survivors had older age (55 ± 16 vs. 45 ± 17, p = 0.014), higher APACHE II score (20 ± 5 vs. 17 ± 5,
p = 0.01), lower white blood cell count (7.68 ± 3.44 vs. 10.48 ± 4.62, p = 0.005), less fever (80.6%vs. 100 %, p = 0.033),
more hypotension (58.1 % vs. 20 %, p = 0.003), more pneumomediastinum (29 % vs. 5 %, p = 0.027). Logistic
regression analysis demonstrated that age [odds ratio (OR)1.051; 95 % CI 1.007-1.097; p = 0.022], white blood cell
count [OR 0.802; 95 % CI 0.670-0.960; p = 0.016], and pneumomediastinum [OR 16.514; 95 % CI 1.330-205.027; p = 0.
029] were independently associated with hospital mortality.
Conclusions: Mortality rate for non-HIV PJP patients requiring ICU admission was still high. Poor prognostic factors
included age, white blood cell count and pneumomediastinum.
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Background
With the widespread use of Pneumocystis jirovecii pneu-
monia (PJP) prophylaxis and highly active antiretroviral
therapy (HAART), the incidence and mortality of PJP in
HIV patients have declined substantially in Europe and
the United States [1, 2]. Current estimates of hospital
mortality for PJP in HIV patients range from 7 % to
11 % [3]. Most importantly, respiratory failure due to
PJP requiring ICU admission was less common in HIV
patients [4]. In contrast, PJP rate is increasing in non-
HIV patient [5] and the reported mortality of PJP in
immunocompromised non-HIV patients ranges from 48 %
to 67 % [3]. The clinical course, and inflammatory response
might contribute to the different mortality rates between
the two groups. In addition, the sample sizes of previous
studies exploring the prognostic factor were small [6–8].
The prognostic factor for severe PJP in the intensive care
unit (ICU) setting has not been well described.
In order to determine the prognostic factors for PJP in
ICU setting, we retrospectively collected data for a con-
secutive series of PJP patients requiring ICU admission
from October 2012 to October 2015.
Methods
Study design
We conducted a bicentric retrospective cohort study in
4 ICUs at 2 academic medical centers, including a
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medical ICU, an emergency ICU, and a general ICU at
Peking Union Medical College Hospital (PUMCH 1800
beds), and a medical ICU at China-Japan Friendship
Hospital (CJFH 1610 beds). All four ICUs contain 83
beds during the study period.
All patients discharged with diagnosis of PJP from
October 2012 to October 2015 were screened for eligi-
bility. Inclusion criteria: (1) PJP, confirmed by Polymer-
ase Chain Reaction (PCR) or methenamine silver stain
of samples from bronchoalveolar lavage fluid (BALF),
aspirate or sputum; (2) HIV tests negative; (3) ICU
admission during index hospitalization due to respira-
tory insufficiency.
Patients without immunocompromised background,
less than 18 years old or pregnant were excluded.
Data collection
Data were gathered retrospectively from medical records at
both PUMCH and CJFH by the investigators (L.C., L-Q.F.,
L.W., and X.H.). Patient identifiers were removed from
the final data sheet and were coded with a numbered
assignment.
Demographic, laboratory, and clinical data were col-
lected, including age, gender, microbiological findings
for PJP, severity of illness based on the acute physiology
and chronic health evaluation (APACHE) II score,
comorbidities, complications, the time of PJP symptom
onset, the time of PJP diagnosis, the time to appropriate
antibiotics administration, and the chest radiographs and
CT scan findings. Data on mechanical ventilation in-
cluded type of oxygen therapy or ventilatory support on
ICU admission; tidal volume, plateau pressure, positive
end-expiratory pressure (PEEP), fraction of inspired oxy-
gen (FiO2) and recruitment maneuver on ICU admis-
sion; maximal tidal volume, maximal PEEP during ICU
stay. Hospital mortality was the primary outcome of our
study.
Definition
(1) PJP was defined as: symptoms and radiographs com-
patible with PJP [9]; confirmed by PCR or methenamine
silver stain of samples from bronchoalveolar lavage fluid
(BALF), aspirate or sputum. (2) ventilator-associated
pneumonia (VAP) was defined as a new lung parenchymal
opacity on a chest radiograph of a patient intubated for
more than 48 h; and simultaneous presentation of two or
more of: purulent secretion from tracheal; temperature of
less than 36 °C or more than 38 °C; white blood cell count
(WBC) of less than 4 × 109/L or more than 10 × 109/L. (3)
Pulmonary aspergillosis was defined by one host factor
criterion, one microbiological criterion and one major
clinical criterion (or 2 minor criteria) according to an
international consensus from experts of the European
Organization for Research and Treatment of Cancer
(EORTC) and the National Institute of Allergy and
Infectious Diseases Mycoses Study Group [10]. (4)
Cytomegalovirus (CMV) infection was confirmed if
pp65-antigenemia assay or CMV DNA assay were posi-
tive [11]. (5) Barotrauma was defined as pneumome-
diastinum or pneumothorax. (6) Pneumomediastinum
was diagnosed as the presence of free air in the medias-
tinal cavity by CT scan or Chest x-ray showing hyperlu-
cent lines outlining the lateral heart borders with
subcutaneous emphysema around neck and chest region.
This study was approved by the institutional review
board of Peking Union Medical College Hospital (S-K116).
Due to the retrospective nature of the study, informed
written consent was waived.
Statistical analysis
For the statistical analysis, continuous data were com-
pared with use of the Student’s t test or Mann-Whitney
test as appropriate. Statistical analysis of non-continuous
dichotomous data was compared by the chi-square test
or the Fisher’s Exact Test as appropriate. Logistic regres-
sion models were used to determine the effect of prog-
nostic factors on hospital death by means of stepwise
backward elimination procedures, after adjusting for co-
variates of which the p values were less than 0.1. All
statistical analyses were performed using SPSS statistical
software (version 22.0; IBM Inc., Armonk, NY). All p values
were two sided, and statistical significances were accepted
for p < 0.05.
Results
Overall, 348 patients were discharged with a diagnosis of
PJP during the study period, of whom 266 met exclusion
criteria. Consequently, 82 patients were available for the
final analysis, including 72 patients PUMCH and 10
patients in CJFH (Fig. 1).
Table 1 shows characteristics and outcomes of con-
firmed PJP in non-HIV patients. The entire 82 patient co-
hort had a mean age 53 ± 17 years of and APACHE II
score of19 ± 5, with 41.4 % male. Most of the patients had
an underlying disease of connective tissue disease (79.3 %)
and history of corticosteroid therapy (84.1 %). All patients
were treated with trimethoprim-sulfamethoxazole (TMP-
SMX). Not a single patient received PJP prophylaxis. PJP
was diagnosed by methenamine silver stain, PCR, or both
in 13, 45, and 24 patients respectively, without any differ-
ence between 2 hospitals (Additional file 1: Table S2). PJP-
PCR positive samples included sputum (n = 5), trachea
aspirate (n = 17), and BALF (n = 49). Methenamine silver
stain positive samples included sputum (n = 4), trachea
aspirate (n = 12), and BALF (n = 19). All pulmonary asper-
gillosis was diagnosed as EORTC probable invasive asper-
gillosis with the presence of a host factor, a clinical
criterion, and a mycological criterion. For the 38 patients
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receiving caspofungin, total days on caspofungin were 8 ±
6. Twenty-five patients received empirical caspofungin
therapy for less than 7 days for suspected invasive fungal
infection. Another 6 patients received caspofungin as a
combination therapy with amphotericin B or voriconazole
for aspergillosis. Although the clinical efficacy of caspo-
fungin as salvage therapy for PJP remained controversial
[12], it was administered in 7 patients in our cohort study
as a salvage regimen of whom 5 patients died during study
period.
During their hospital stay, 62 (75.6 %) of the 82
patients died. Compared with survivors, the non-
survivors had older age (55 ± 16 vs. 45 ± 17, p = 0.014),
higher APACHE II score (20 ± 5 vs. 17 ± 5, p = 0.01),
lower WBC (7.68 ± 3.44 vs. 10.48 ± 4.62, p = 0.005), less
fever (80.6%vs. 100 %, p = 0.033), more hypotension
(58.1 % vs. 20 %, p = 0.003), and more pneumomediasti-
num (29 % vs. 5 %, p = 0.027), while the difference was
not statistically significant for lymphocyte counts, CD4
cell count, type of respiratory support on ICU admission.
Four patients received high-frequency oscillatory ventila-
tion and one patient received extracorporeal membrane
oxygenation. All these five patients died during the hos-
pital stay.
To investigate the role of potential confounding prog-
nostic factors, a multivariate analysis was performed for
hospital mortality (Table 2). The Hosmer and Lemeshow
goodness-of-fit test were not rejected (p = 0.640), indicat-
ing adequate model fit. No interaction terms were found
to be significant in this model, and there was no collinear-
ity between any of the independent variables. The multi-
variate model indicated that age [odds ratio (OR)1.051;
95 % CI 1.007-1.097; p = 0.022], WBC [OR 0.802; 95 % CI
0.670-0.960; p = 0.016], and pneumomediastinum [OR
16.514; 95 % CI 1.330-205.027; p = 0.029] were independ-
ently significantly associated with hospital mortality.
CT scans were performed for all those 82 patients on
ICU admission. Pneumomediastinum was confirmed by
CT in 14 patients and chest x-ray plus subcutaneous
emphysema in 5 patients. Six patients developed pneu-
momediastinum before hospital admission. Other 13
patients had time intervals between ICU admission and
pneumomediastinum with a mean of 9 days (range 2–30
days). The potential risk factors contributed to pneumo-
mediastinum were listed in Table 3. There was statisti-
cally significant difference in the percentage of patients
treated with non-rebreathing mask (NRM) on ICU
admission between pneumomediastinum and non-
pneumomediastinum (47.4 % vs. 23.8 %, p = 0.048).
Tidal volume, plateau pressure, and PEEP was similar
between those two groups.
Discussion
In this bicentric retrospective observational study across
4 Chinese ICUs, we found that age, WBC, and pneumo-
mediastinum were significantly associated with hospital
mortality in non-HIV immunocompromised patients
with severe PJP who had been admitted to ICU. Use of
non-rebreathing mask might contribute to the develop-
ment of pneumomediastinum.
The most interesting finding of our study was that pneu-
momediastinum was associated with increased hospital
mortality. Pneumomediastinum is the presence of extra-
alveolar air in the mediastinum, which is believed to arise
from free air leaking from ruptured alveoli. It was de-
scribed as an uncommon complication of opportunistic in-
fections in HIV-infected patients [13, 14]. However, 24.4 %
patients in our study developed pneumomediastinum. The
Fig. 1 The patient flowchart with respect to inclusion and exclusion
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Table 1 Characteristics and outcomes of confirmed pneumocystis jiroveci pneumonia in non-HIV patients
Survivors Non-survivors P
valueN = 20 N = 62
Age, mean ± SD 45 ± 17 55 ± 16 0.014
Male, n (%) 6(30.0) 28(45.2) 0.231
Apache II, mean ± SD 17 ± 5 20 ± 5 0.010
Underlying disease
CTD, n (%) 16(80.0) 49(79.0) 0.926
ILD, n (%) 1(5.0) 1(1.6) 0.431
Dermatomyositis, n (%) 1(5.0) 9(14.5) 0.438
Organ transplant, n (%) 2(10.0) 1(1.6) 0.146
Hematologic malignancy, n (%) 0(0) 3(4.8) 0.427
Solid tumor, n (%) 2(10.0) 2(3.2) 0.249
Corticosteroid therapy, n (%) 17(94.4) 52(89.7) 0.539
Symptom
Fever, n (%) 20(100) 50(80.6) 0.033
Dyspnea, n (%) 19(95.0) 56(90.3) 0.515
Cough, n (%) 15(75) 42(67.7) 0.540
Microbiological methods
PCR, n (%) 17(85.0) 54(87.1) 0.811
Methenamine silver stain, n (%) 11(55.0) 24(38.7) 0.200
Repiratory samples
Sputum, n (%) 0(0) 6(9.7) 0.148
Trachea aspirate, n (%) 6(30.0) 16(25.8) 0.713
Bronchoalveolar lavage, n (%) 14(70.0) 40(64.5) 0.653
Laboratory findings
White blood cell counts, mean ± SD 10.48 ± 4.62 7.68 ± 3.44 0.005
lymphocyte counts, mean ± SD 678 ± 600 514 ± 441 0.117
CD4 cell counts, mean ± SD 215 ± 225 159 ± 343 0.510
PaO2/FiO2 on ICU admission 161 ± 69 131 ± 65 0.064
Radiographic findings
Ground glass opacities, n (%) 20(100.0) 62(100.0)
Bilateral symmetric, n (%) 17(85.0) 55(88.7) 0.700
Co-infections
Bacteremia, n (%) 2(10.0) 6(9.7) 0.966
VAP, n (%) 5(25.0) 27(43.5) 0.139
Aspergillosis, pulmonary, n (%) 5(25.0) 13(21.0) 0.705
Cytomegalovirus, n (%) 10(50.0) 40(64.5) 0.247
Complications
Hypotension, n (%) 4(20.0) 36(58.1) 0.003
NE(mcg/kg/min), mean ± SD 0.22 ± 0.16 0.39 ± 0.36 0.439
Barotrauma
Pneumothorax, n (%) 2(10.0) 9(14.5) 0.465
Pneumomediastinum, n (%) 1(5.0) 18(29) 0.027
Intervals
Onset to diagnosis, days, mean ± SD 15 ± 12 14 ± 10 0.488
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incidence rate discrepancies may be due to different under-
lying disease (HIV vs. Non-HIV) and few reported
incidence rate in previous studies. A retrospective radio-
graphic analysis reported an incidence rate of 11.1 % (4 of
36) in a cohort of moderate non-HIV PJP patients with a
mortality rate of 33.3 % [15]. We also found more pneu-
momediastinum developed in the NRM group. This might
be explained by higher trans-pulmonary pressure and tidal
volume during spontaneous breath resulting in air leak,
which was consistent with a previous report of HIV
patients [13]. Delayed intubation was considered as a risk
factor for worse outcome [6]. Although there was no differ-
ence in the time interval from symptom onset to intub-
ation in our study, use of non-rebreathing mask instead of
positive pressure support on ICU admission suggested
delay intubation which was very difficult to define.
Development of pneumothorax was independently asso-
ciated with increased mortality in previous studies [6, 16].
We did not find any difference in mortality between pa-
tients with and without pneumothorax. Protective lung
ventilation strategies might account for the different find-
ings. The tidal volumes in our study were smaller than
Festic and colleagues (7 ml/kg vs. 10 ml/kg). Despite the
application of protective lung ventilation, one fourth pa-
tient in this cohort developed pneumomediastinum, which
suggested that pneumomediastinum was not a complica-
tion of intervention. As Cho et al. [17] reported, the
development of the pulmonary cysts and bronchiectasis
that were noted in follow up CT but were not visible on
CT at admission could be risk factors for development of
pneumomediastinum.
We also found lower WBC was related to increased
mortality. Although WBC has never been reported as
risk factors, previous study [18] suggested a trend of
higher WBC in non-HIV patients and survivors, which
was consistent with our findings.
Overall mortality of the patients in our study was
75.6 %. Although the reported mortality rates of ICU non-
HIV patients with PJP in previous studies were 38.9-
84.2 % [6–8, 18–28] (Additional file 2: Table S1), most of
the mortality rates were less than 70 %, which were lower
than that of our study. The high hospital mortality rate in
our study possibly was related to different underlying dis-
eases and no prophylaxis of PJP for those patients. How-
ever, although prophylaxis for PJP was recommended for
HIV patients, the efficacy of prophylaxis for immunocom-
promised non–HIV patients has not been well established
[29–31], especially for the patients with underlying disease
of connective tissue disease. In a recent study of ICU pa-
tients with PJP, adjunctive steroid was associated with in-
creased mortality [16]. This might be the cause of high
hospital mortality in our study. Considering that most of
the patients in our study received steroid therapy before
ICU admission, the use of steroid was not avoidable.
Moreover, there was no difference in steroid therapy be-
tween survivors and non-survivors, and the effects of
other covariates remained significant.
In a retrospective study, Chen and colleagues re-
ported the characteristics and prognostic factors of 69
HIV-negative patients with PJP from PUCMH during
10-year study period [25]. In comparison, we had
enrolled 72 patients with confirmed PJP during a 3-
year period in our cohort (Additional file 1: Table S2,
Additional file 3: Table S3). Increasing awareness of
the disease in immunocompromised patients among
Table 1 Characteristics and outcomes of confirmed pneumocystis jiroveci pneumonia in non-HIV patients (Continued)
Onset to intubation, days, mean ± SD 10 ± 6 12 ± 11 0.786
Onset to TMP/SMZ, days, mean ± SD 14 ± 18 11 ± 10 0.538
Respiratory support
IPPV during ICU stay, n (%) 16(80.0) 59(95.2) 0.057
NPPV on ICU admission, n (%) 4(20.0) 8(12.9) 0.474
IPPV on ICU admission, n (%) 10(50.0) 36(58.1) 0.527
NRM on ICU admission, n (%) 6(30.0) 18(29.0) 0.934
Medication
Adjunctive steroid, n (%) 16(80.0) 48(77.4) 0.808
Caspofungin, n (%) 7(35.0) 31(50.0) 0.242
Values are expressed as the mean ± SD or Number (%), unless otherwise indicated. CTD Connective Tissue Disease, ILD Interstitial lung Disease, PCR polymerase
chain reaction, BALF bronchoalveolar lavage fluid, VAP ventilator-associated pneumonia, NE norepinephrine, TMP/SMZ trimethoprim-sulfamethoxazole, IPPV Invasive
positive pressure ventilation, NPPV noninvasive positive pressure ventilation, NRM non-rebreathing mask
Table 2 Multivariate analysis for predictors of death in patients
with confirmed pneumocystis jiroveci pneumonia in non-HIV
patients
Multivariate analysis Wald stat. P value
Odds Ratio (95 % CI)
Age 1.051(1.007-1.097) 5.238 0.022
White blood cell counts 0.802 (0.670-0.960) 5.787 0.016
Pneumomediastinum 16.514(1.330-205.027) 4.761 0.029
The risk factors removed from the logistic regression model including: APACHE
II; Fever; PaO2/FiO2 on ICU admission; IPPV on ICU admission; Hypotension
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Table 3 Risk factors for Pneumomediastinum of confirmed pneumocystis jiroveci pneumonia in non-HIV patients
Pneumomediastinum Non-Peumomediastinum P value
N = 19 N = 63
Age, mean ± SD 51 ± 19 53 ± 16 0.606
Male, n (%) 8(42.1) 26(41.3) 0.948
Apache II, mean ± SD 19 ± 5 19 ± 5 0.948
Underlying conditions
CTD, n (%) 16(84.2) 49(77.8) 0.544
ILD, n (%) 1(5.3) 1(1.6) 0.412
Dermatomyositis, n (%) 1(5.3) 9(14.3) 0.440
Organ transplant, n (%) 1(5.3) 2(3.2) 0.552
Hematologic malignancy, n (%) 0(0) 3(4.8) 0.448
Solid tumor, n (%) 1(5.3) 3(4.8) 0.659
Corticosteroid therapy, n (%) 17(89.5) 52(82.5) 0.722
Symptom
Fever, n (%) 17(89.5) 53(84.1) 0.563
Dyspnea, n (%) 19(100) 56(88.9) 0.192
Cough, n (%) 14(73.7) 43(68.3) 0.652
Laboratory findings
White blood cell counts, mean ± SD 7.85 ± 2.92 8.52 ± 4.18 0.518
lymphocyte counts, mean ± SD 601 ± 618 540 ± 444 0.717
CD4 cell counts, mean ± SD 246 ± 583 156 ± 186 0.886
PaO2/FiO2 on ICU admission 144 ± 53 136 ± 70 0.663
Co-infections
Aspergillosis, pulmonary, n (%) 3(15.8) 15(23.8) 0.544
Cytomegalovirus, pulmonary, n (%) 12(63.2) 38(60.3) 0.824
Intervals
Onset to diagnosis, days, mean ± SD 13 ± 5 14 ± 12 0.480
Onset to intubation, days, mean ± SD 11 ± 6 12 ± 11 0.753
Onset to TMP/SMZ, days, mean ± SD 9 ± 6 12 ± 13 0.230
Respiratory support
IPPV during ICU stay, n (%) 18(94.7) 57(90.5) 0.560
VT maximal(ml/kg), mean ± SD 7.1 ± 2.0 8.1 ± 2.4 0.208
PEEP maximal(cmH2O), mean ± SD 11 ± 5 10 ± 4 0.415
NPPV on ICU admission, n (%) 3(15.8) 9(14.3) 0.871
IPAP(cmH2O), mean ± SD 14 ± 3 11 ± 3 0.118
EPAP(cmH2O), mean ± SD 7 ± 2 7 ± 2 0.980
IPPV on ICU admission, n (%) 7(36.8) 39(61.9) 0.054
VT(ml/kg), mean ± SD 6.8 ± 1.0 7.1 ± 1.2 0.462
Pplat(cmH2O), mean ± SD 25 ± 4 24 ± 6 0.821
PEEP(cmH2O), mean ± SD 10 ± 4 10 ± 4 1.000
FiO2, mean ± SD 0.74 ± 0.15 0.65 ± 0.18 0.066
Recruitment maneuvers, n (%) 6(35.3) 17(30.9) 0.735
NRM on ICU admission, n (%) 9(47.4) 15(23.8) 0.048
Values are expressed as the mean ± SD or Number (%), unless otherwise indicated. VT tidal volume of predicted body weight, Pplat plateau pressure, PEEP positive
end-expiratory pressure, FiO2 fraction of inspired oxygen, IPAP inspiratory positive airway pressure, EPAP expiratory positive airway pressure
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clinicians and widespread implementation of PCR
technique for PJP diagnosis might account for the dis-
crepancy between Chen’s study and ours.
Limitation
The main limitation of the current study was the retro-
spective nature of the investigation. Considering the rela-
tively low incidence of PJP in ICU, it would be reasonable
to prospectively collect data in the future investigation
based on current finding. The second limitation was the
small population recruited. To our best knowledge, only
one study [8] included more ICU PJP patients than ours
(88 vs. 82). However, because we focused on the prognos-
tic factors for PJP in an ICU setting, our findings were
more helpful to the ICU patients. Third, PJP was diag-
nosed on the basis of PJP PCR result in some patients.
Due to the colonization of PJP, there is a possibility of false
positive results. According to recent studies [32, 33],
quantitative real-time Polymerase Chain Reaction (PCR)
might be helpful in discriminating colonization from in-
fection. However, those real-time PCR was not available in
our centers during the study period. Nevertheless, all pa-
tients included in analysis had symptoms and their radio-
graphic findings were compatible with PJP.
Conclusion
Our finding suggested that PJP in non-HIV patients re-
quiring ICU admission remains a challenge for clinician.
Poor prognostic factors included older age, lower WBC,
and development of pneumomediastinum.
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